Fermion Oy Fermion Oy

X
[{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Population Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lubrizol Expands Partnership with the Population Council","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed"},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Welton Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lubrizol Licenses Award-Winning Apisolex\u2122 Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Lubrizol Life Science Health

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The license will allow Welton to use the Apisolex excipient worldwide to develop and commercialize a novel formulation of WP-038 (SN-38) to treat colorectal and associated gastro-intestinal cancers.

            Lead Product(s): Irinotecan Hydrochloride,Apisolex

            Therapeutic Area: Oncology Product Name: WP-038

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Welton Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This builds on a decades-long partnership between the two organizations to optimize the delivery of several vaginal products, including the Population Council’s proprietary progestin, Nestorone®, and MIV-150, and manufacturing lead formulations for toxicology.

            Lead Product(s): Segesterone Acetate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nestorone

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Population Council

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY